dehydroabietylamine has been researched along with Carcinoma, Hepatocellular in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahn, KS; Chinnathambi, A; Govindasamy, C; Jung, YY; Mohan, CD; Rangappa, KS; Rangappa, S; Sin, ZW | 1 |
| Ali, FI; Aslam, A; Baig, JA; Hashmi, IA; Muhammad, S; Mustufa, MA; Ozen, C; Ozturk, M; Solangi, IB; Ul Hasan Naqvi, N; Yildiz, G | 1 |
2 other study(ies) available for dehydroabietylamine and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Leelamine Exerts Antineoplastic Effects in Association with Modulating Mitogen‑Activated Protein Kinase Signaling Cascade.
Topics: Abietanes; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Liver Neoplasms; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases | 2022 |
Synthesis and bio-molecular study of (+)-N-Acetyl-α-amino acid dehydroabietylamine derivative for the selective therapy of hepatocellular carcinoma.
Topics: Abietanes; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; G2 Phase Cell Cycle Checkpoints; Humans; Inhibitory Concentration 50; Liver Neoplasms | 2016 |